Compare JBSS & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | BIOA |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.1M | 776.6M |
| IPO Year | 1994 | N/A |
| Metric | JBSS | BIOA |
|---|---|---|
| Price | $81.51 | $16.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $109.00 | $51.50 |
| AVG Volume (30 Days) | 56.1K | ★ 430.0K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $1,107,246,000.00 | N/A |
| Revenue This Year | $5.58 | $846.41 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.79 | ★ N/A |
| Revenue Growth | ★ 3.79 | N/A |
| 52 Week Low | $59.07 | $3.64 |
| 52 Week High | $85.15 | $24.00 |
| Indicator | JBSS | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 41.04 |
| Support Level | $61.12 | $15.47 |
| Resistance Level | $81.93 | $21.75 |
| Average True Range (ATR) | 2.53 | 1.10 |
| MACD | 0.23 | -0.05 |
| Stochastic Oscillator | 66.89 | 31.76 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.